Ehlers-Danlos syndrome is usually described as a condition of stretchy skin and hypermobile joints. That description is accurate but dangerously incomplete. Connective tissue is the structural scaffolding of every organ system in the body, and the gastrointestinal tract is no exception. The smooth muscle layers of the intestinal wall, the structural support for the enteric nervous system, and the framework housing the interstitial cells of Cajal all depend on intact connective tissue. When that tissue is defective, as it is in EDS, gut function suffers. The result is a pattern of dysmotility, visceral hypersensitivity, and bacterial overgrowth that affects up to 75% of EDS patients and is frequently misdiagnosed as IBS.
What is Ehlers-Danlos syndrome?
Ehlers-Danlos syndrome encompasses 13 recognized subtypes, each caused by defects in collagen or related proteins. The hypermobile type (hEDS) is by far the most common, estimated to affect 1 in 500 to 1 in 5,000 people, though many experts believe it is significantly underdiagnosed. Unlike most other EDS subtypes, hEDS does not yet have an identified genetic mutation; diagnosis is based on clinical criteria including generalized joint hypermobility, systemic features of connective tissue fragility, and exclusion of other conditions. Other EDS subtypes include classical (cEDS), vascular (vEDS), and kyphoscoliotic (kEDS), each with specific genetic mutations in collagen or collagen-processing genes. While GI symptoms can occur in any subtype, they are most thoroughly studied and most commonly reported in hEDS.
How EDS affects the gastrointestinal tract
The GI tract is a muscular tube wrapped in connective tissue. The intestinal wall has multiple layers: the mucosa (inner lining), the submucosa (connective tissue layer containing blood vessels and nerves), the muscularis (smooth muscle layers responsible for peristalsis), and the serosa (outer covering). Connective tissue provides structural integrity to all of these layers. In EDS, defective connective tissue can weaken the mechanical support for smooth muscle contraction, alter the compliance and stretch characteristics of the intestinal wall, impair the structural framework that houses the enteric nervous system, and potentially affect the extracellular matrix surrounding the interstitial cells of Cajal. The net effect is a gut that does not contract efficiently, does not propel contents effectively, and is prone to functional obstruction, gastroparesis, and the stagnation conditions that promote SIBO.
The role of interstitial cells of Cajal in EDS
The interstitial cells of Cajal (ICC) are the pacemaker cells of the gut. They generate the slow-wave electrical activity that coordinates smooth muscle contraction and drives peristalsis and the migrating motor complex. ICC are embedded in the connective tissue between the smooth muscle layers of the intestinal wall. In EDS, the theory is that defective extracellular matrix may compromise ICC function, either by disrupting the mechanical signaling between ICC and smooth muscle cells or by altering the structural environment ICC need to maintain their network. While direct biopsy evidence of ICC loss in EDS patients is limited, the clinical pattern of impaired MMC function, delayed transit, and recurrent SIBO is consistent with ICC dysfunction. This is an active area of research with significant implications for understanding why EDS patients develop SIBO at such high rates.
The EDS-POTS-SIBO triad
Clinicians who specialize in EDS have increasingly recognized a triad of conditions that co-occur with striking frequency: hypermobile EDS, postural orthostatic tachycardia syndrome (POTS), and SIBO. POTS is a form of autonomic dysfunction characterized by an excessive increase in heart rate (30+ beats per minute) upon standing, often accompanied by lightheadedness, brain fog, fatigue, and exercise intolerance. An estimated 50-80% of hEDS patients meet criteria for POTS. The autonomic nervous system directly regulates gut motility. When autonomic function is impaired, gastric emptying slows, the MMC fires less frequently, and the conditions for SIBO are created. The triad therefore represents a cascade: defective connective tissue (EDS) leads to autonomic dysfunction (POTS), which leads to dysmotility, which leads to bacterial overgrowth (SIBO). Each component reinforces the others.
- EDS (hypermobility): defective connective tissue affects gut wall structure and ICC function.
- POTS (autonomic dysfunction): impaired autonomic regulation slows gastric emptying and reduces MMC frequency.
- SIBO (bacterial overgrowth): dysmotility from both structural and autonomic causes creates stagnation conditions.
- Each component can worsen the others: SIBO causes inflammation that may aggravate autonomic dysfunction; POTS symptoms worsen with the dehydration from SIBO-related diarrhea; malnutrition from SIBO impairs connective tissue repair.
GI symptoms in EDS: beyond bloating
The range of GI symptoms in EDS extends well beyond the bloating and diarrhea typical of SIBO. EDS patients commonly report gastroparesis (delayed stomach emptying causing nausea, early satiety, and vomiting), gastroesophageal reflux (due to lax lower esophageal sphincter), functional obstruction (pseudo-obstruction where the gut stops moving without a physical blockage), rectal prolapse (due to pelvic floor connective tissue weakness), hernias (hiatal, inguinal, and other types), and visceral hypersensitivity (amplified perception of normal gut sensations). These symptoms are frequently attributed to anxiety, IBS, or functional disorders before the underlying connective tissue diagnosis is made. Recognizing the EDS connection changes the management approach because treatments targeting connective tissue-related dysmotility differ from standard IBS management.
âšī¸If you have joint hypermobility, stretchy or fragile skin, chronic bloating, POTS symptoms, and a history of being told your GI symptoms are just IBS or anxiety, consider evaluation for Ehlers-Danlos syndrome. The Beighton hypermobility score is a simple self-screening starting point.
Treatment considerations for EDS-associated SIBO
SIBO treatment in EDS patients follows the same general principles as SIBO treatment in other populations: antibiotic or herbal antimicrobial therapy to reduce the overgrowth, followed by prokinetic therapy to prevent relapse. However, EDS-associated SIBO has a higher relapse rate because the underlying connective tissue defect is permanent. Prokinetic therapy is therefore especially important and often needs to be continued long-term. Commonly used prokinetics include low-dose erythromycin (50-100 mg at bedtime), prucalopride, and low-dose naltrexone. Addressing the POTS component with adequate hydration, electrolyte supplementation, and sometimes medications like fludrocortisone or midodrine may also improve gut motility indirectly by supporting autonomic function. Dietary modifications (smaller, more frequent meals; reduced FODMAP intake during flares) provide symptomatic support.
Frequently Asked Questions
Can you have EDS-related SIBO without being diagnosed with EDS?
Yes. Many people with hypermobile EDS are undiagnosed for years or decades. If you have joint hypermobility, frequent injuries, stretchy skin, and chronic GI symptoms, the possibility of EDS should be explored even if it has never been formally considered.
Does treating POTS help with SIBO?
It can. Improving autonomic function through hydration, salt loading, compression garments, and medications may enhance gut motility and reduce SIBO relapse risk. Treating POTS is not a standalone SIBO cure but is an important component of a comprehensive management plan.
Is EDS-related SIBO harder to treat than other types?
The initial eradication responds to the same therapies. However, the relapse rate tends to be higher because the underlying connective tissue and motility defects are permanent. Long-term prokinetic therapy and lifestyle modifications are usually needed to maintain remission.
â ī¸This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition.